Showing 1 - 10 of 2,765
This paper examines the relationship between drug price and drug quality and how it varies across two of the most common regulatory regimes in the pharmaceutical market: minimum efficacy standards (MES) and a mix of minimum efficacy standards and price control mechanisms (MES+PC). Through a...
Persistent link: https://www.econbiz.de/10012768128
paper, we begin by examining the efficiency implications of this joint regulation of drug safety. We find that joint … regulation of drug safety can be inefficient when the regulatory authority mandates a binding and well enforced level of safety …
Persistent link: https://www.econbiz.de/10012750312
This paper analyzes the relationship between postmarketing promotional activity and reporting of adverse drug events by modeling the interaction between a welfare maximizing regulator (the FDA) and a profit maximizing firm. In our analysis demand is sensitive to both promotion and regulatory...
Persistent link: https://www.econbiz.de/10012753261
This paper examines the role of regulation and competition in generic markets. Generics offer large potential savings … to payers and consumers of pharmaceuticals. Whether the potential savings are realized depends on the extent of generic …
Persistent link: https://www.econbiz.de/10013122264
Pharmaceutical firms' use of secondary patents to extend periods of exclusivity generates concerns among policymakers worldwide. In response, some developing countries have introduced measures to curb the grant of these patents. While these measures have received considerable attention, there is...
Persistent link: https://www.econbiz.de/10012964387
Efforts to strengthen the global patent system for pharmaceuticals continue to be controversial, and what will likely … seven years after those in another. Both price regulation and intellectual property rights influence these outcomes. The …
Persistent link: https://www.econbiz.de/10013224385
We examine the relationship between patent protection for pharmaceuticals and investment in development of new drugs …. Patent protection has increased around the world as a consequence of the TRIPS Agreement, which specifies minimum levels of … intellectual property protection for members of the World Trade Organization. It is generally argued that patents are critical for …
Persistent link: https://www.econbiz.de/10013324637
This paper compares the clinical trial strategies and performance of large, established (quot;maturequot;) biopharmaceutical firms to those of smaller (quot;early stagequot;) firms that have not yet successfully developed a drug. We study a sample of 235 cancer drug candidates that entered...
Persistent link: https://www.econbiz.de/10012752635
Overdose deaths involving opioids have increased dramatically since the mid-1990s, leading to the worst drug overdose epidemic in U.S. history, but there is limited empirical evidence on the initial causes. In this paper, we examine the role of the 1996 introduction and marketing of OxyContin as...
Persistent link: https://www.econbiz.de/10012858413
Prior work considers effects of prescribing restrictions on opioid use but not upstream implications for pharmaceutical marketing activities, despite the inordinate role many believe marketing played in the crisis. Our study proposes a stylized model of pharmaceutical payments and investigates...
Persistent link: https://www.econbiz.de/10012861727